P-77: Follicular Fluid Concentrations of Interleukin-6, Interleukin-8, TNF-α and Interleukin 10 in Polycystic Ovarian Syndrome Women
While the etiology of PCOS has continued to remain a mystery, there can be found some evidence in support of the presence of chronic low-grade inﬂammation in women with this syndrome. One of the most significant manifestations of chronic inﬂammation is Pro-inﬂammatory cytokines. Therefore, the aim of this prospective study was to investigate the pattern of proinflammatory and anti-inflammatory cytokines in the follicular fluid (FF) of PCOS women undergoing in vitro fertilization (IVF).
Materials and methods
Eighty women who met the selection criteria were recruited, and the FF was obtained during the follicular aspiration. Hence, we classify them as follows: (A) PCOS women; (B) Control women with normal ovulatory function who underwent IVF for treatment of tubal and/ or male infertility. Obtained FF from each patient was centrifuged at 300 g for 10 min. The supernatant was used to determine the concentration of a quantification of pro inflammatory cytokines interleukin (IL)-8 , IL-6, IL-10, and tumor necrosis factor-alpha (TNF-α) which was measured by the sandwich enzyme immunoassay ELISA based on a monoclonal antibody specific for them (Boster Biological Technology ltd, USA), according to the manufacturer's instructions.
After BMI was controlled, there was a significant increment in the concentration of inflammatory cytokines IL-8 (187 ± 43.01 pg/ml), IL-6 (29.39 ± 2.75 pg/ml) and TNF-α (6.35 ±1.7 pg/ml) in the FF of PCOS women undergoing controlled ovarian hyperstimulation versus control women(141.92 ± 28.87, 7.90 ± 0.28 and 4.02 ± 0.94 pg/ml respectively, P<0.05). In addition, comparing PCOS and control group, we observed significantly lower levels of IL-10 concentration in PCOS women (4.02 ± 0.26 vs. 8.69 ± 1.10 pg/ml, P < 0.001).
This result confirms the point that we can have the presence of a chronic low-grade inﬂammation and an involvement of the immune system in women with poly cystic ovarian syndrome. Therefore, it seems that targeting this inflammatory process by means of anti-inflammatory agents might be a good solution to the current treatment.